Literature DB >> 32074433

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. Reply.

Kevin R Flaherty1, Athol U Wells2, Kevin K Brown3.   

Abstract

Entities:  

Year:  2020        PMID： 32074433     DOI： 10.1056/NEJMc1917224

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis.

Authors:  Ayodeji Adegunsoye; Julie Morisset; Chad A Newton; Justin M Oldham; Eric Vittinghoff; Angela L Linderholm; Mary E Strek; Imre Noth; Christine Kim Garcia; Paul J Wolters; Brett Ley
Journal:  Eur Respir J       Date:  2021-03-04       Impact factor: 16.671

2.  Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Ayodeji Adegunsoye; Shehabaldin Alqalyoobi; Angela Linderholm; Willis S Bowman; Cathryn T Lee; Janelle Vu Pugashetti; Nandini Sarma; Shwu-Fan Ma; Angela Haczku; Anne Sperling; Mary E Strek; Imre Noth; Justin M Oldham
Journal:  Chest       Date:  2020-05-22       Impact factor: 9.410

3.  Safety and accuracy of transbronchial lung cryobiopsy in diagnosing desquamative interstitial pneumonia.

Authors:  Jun-Ge Zhao; Guo-Wu Zhou; Ling Zhao; Min Liu; Yan-Hong Ren; Hua-Ping Dai
Journal:  Clin Respir J       Date:  2022-03-01       Impact factor: 1.761

Review 4.  The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.

Authors:  Siavash Bolourani; Max Brenner; Ping Wang
Journal:  J Mol Med (Berl)       Date:  2021-07-13       Impact factor: 4.599
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.